How to access Fabhalta from Kuwait — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Kuwaiti patient with paroxysmal nocturnal hemoglobinuria (PNH) may receive a prescription for Fabhalta (iptacopan) from their treating haematologist. Fabhalta is FDA-approved for PNH in adult patients, and it is manufactured by Novartis. It is the first oral, twice-daily monotherapy approved for PNH — a meaningful differentiator from the IV or subcutaneous regimens of Soliris, Ultomiris, and Empaveli. Its mechanism is Factor B inhibition, which blocks the alternative complement pathway upstream. In Kuwait, Fabhalta may not yet be broadly registered, which is why your haematologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Fabhalta is an oral capsule taken 200 mg twice daily. Because it inhibits the alternative complement pathway, it carries a US boxed warning regarding serious infections caused by encapsulated bacteria (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae), which is why vaccination per current ACIP recommendations is a gating step before therapy begins, as is enrolment in the US REMS program. Internationally, equivalent manufacturer risk-minimisation measures apply. Your treating haematologist confirms PNH diagnosis (flow cytometry), vaccination status, and the dosing plan per FDA labeling.
Is Fabhalta legally importable into Kuwait?
Yes — through the Kuwait Ministry of Health (MoH) Drug and Food Control Administration named-patient framework. The pathway allows a Kuwait-licensed physician to request import of a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For iptacopan specifically, international access respects the manufacturer's controlled-distribution program and the encapsulated-organism-infection risk-minimisation gating.
How the pathway works, step by step
- Consultation with your treating haematologist. PNH diagnosis (flow cytometry), prior therapy history (including any prior C5-inhibitor exposure), and vaccination review.
- Vaccination program. Pneumococcal, meningococcal (A/C/W/Y and B), and Hib vaccinations per current ACIP recommendations, completed at least 2 weeks before first dose where feasible.
- Kuwait MoH named-patient application. Your physician files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner, aligned with the manufacturer's controlled-distribution model.
- Shipment. Fabhalta ships at controlled room temperature; no cold-chain is required.
- Arrival and oral dosing start. The treating physician initiates oral dosing.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming PNH diagnosis with flow-cytometry evidence, prior therapy history, and Fabhalta as the indicated treatment
- Verification of Kuwait medical licence
- Patient identifier
- Vaccination documentation (pneumococcal, meningococcal A/C/W/Y and B, Hib)
- Planned twice-daily oral dosing schedule and projected monthly capsule supply
Reserve Meds provides a physician documentation kit that bundles the templates Kuwait MoH reviewers expect to see for complement inhibitors, including the encapsulated-organism vaccination block.
Costs and timing
Fabhalta's US cash-pay reference price sits in a broad indicative range — the annualised treatment cost for PNH falls in the USD 500,000–650,000 range in US list pricing. International logistics, Kuwait MoH documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for the first dispensed supply after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted (vaccination lead time may extend this).
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Fabhalta specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody and aligned with the manufacturer's controlled-distribution program.
- Documentation. Regulatory package for your physician and for Kuwait MoH review, including the vaccination risk-minimisation block.
- Logistics. Controlled-room-temperature shipment.
- Concierge case lead. A named point of contact.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.
Frequently asked
Is this legal in Kuwait? Yes, when executed through the Kuwait MoH named-patient framework with appropriate documentation.
What about vaccinations? The encapsulated-organism-infection warning is load-bearing. Vaccination against meningococcus, pneumococcus, and Hib per current recommendations must be completed before starting Fabhalta, ideally at least 2 weeks before first dose.
How does Fabhalta compare with Soliris, Ultomiris, or Empaveli? Soliris and Ultomiris are IV C5 inhibitors; Empaveli is a subcutaneous C3 inhibitor via pump; Fabhalta is an oral, twice-daily Factor B inhibitor used as monotherapy. For patients prioritising oral administration and avoiding infusions, Fabhalta is often considered first. Your haematologist chooses based on haemolysis pattern, disease history, and dosing preference.
Will private insurance cover this? Cash-pay is the default. Some Kuwait private insurers reimburse PNH therapy on escalated review; we supply documentation but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Fabhalta coordination in Kuwait.
Add me to the Fabhalta waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.